VistaGen Therapeutics, Inc.
(NASDAQ : VTGN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-1.19%194.101.2%$601.39m
GILDGilead Sciences, Inc.
-0.74%67.070.9%$499.60m
CELGCelgene Corporation
1.75%67.921.2%$484.99m
BIIBBiogen Inc.
-0.39%318.221.3%$464.31m
ILMNIllumina, Inc.
2.81%309.533.5%$397.45m
REGNRegeneron Pharmaceuticals, Inc.
1.86%343.552.6%$297.03m
VRTXVertex Pharmaceuticals Incorporated
1.38%161.971.9%$262.10m
AAgilent Technologies, Inc.
1.01%68.201.5%$218.11m
ALXNAlexion Pharmaceuticals, Inc.
2.22%119.412.0%$204.99m
SRPTSarepta Therapeutics, Inc.
0.63%117.9115.4%$146.92m
LGNDLigand Pharmaceuticals Incorporated
2.71%152.9023.1%$141.12m
EXASExact Sciences Corporation
3.45%66.9725.3%$135.03m
TSROTESARO, Inc.
-4.14%40.7214.4%$132.98m
NKTRNektar Therapeutics
-0.84%37.805.6%$120.95m
INCYIncyte Corporation
1.20%64.352.5%$114.31m

Company Profile

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines for depression and other diseases and disorders of the central nervous system. It focuses on AV-101 product, an oral, non-opioid and non-sedating therapy that offers the potential to be a new at-home treatment for multiple central nervous system indications with high-unmet medical need. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.